


**CURRICULUM VITAE**  
**REGINA BERKOVICH MD, PhD**  
**JANUARY 15, 2021**

Regina Berkovich MD, PhD Inc.  
8727 BEVERLY BLVD, STE B  
WEST HOLLYWOOD, CA 90048  
310-474-9595  
reginaberkovichmd@gmail.com

 6-30-21

**EDUCATION AND PROFESSIONAL APPOINTMENTS**

**EDUCATION:**

1985	High School 135, Kazan, Russia (Summa Cum Laude and Gold Medal)
1991	Medical Doctor, Medicine, Kazan State Medical University, Kazan, Russia (Summa Cum Laude and Red Diploma)

**POST-GRADUATE TRAINING:**

1991-1992	Internship, Internal Medicine, Psychiatry and Neurology, Prof. David Mendelevich MD, PhD, Kazan State Medical University, Kazan, Russia
1992-1995	Clinical Fellowship, Clinical Neurology and Neuro-Pharmacology, Prof. Irina Zimakova MD, PhD Department of Psychiatry and Neurology, Kazan State Medical Academy, Kazan, Russia
1999-2001	Residency, Neurology, Prof. Alexander Skoromec MD, PhD, Department of Neurology, St.-Petersburg Pavlov State Medical University, St.-Petersburg, Russia
2003-2005	Clinical Fellowship, Multiple Sclerosis, Associate Professor Normal Kachuck MD and Professor Leslie Weiner MD, Department of Neurology, University of Southern California, Los Angeles, CA.
2006-2008	California Professional Code 2113 based clinical training for foreign medical graduate while being a faculty of USC Neurology

**HONORS, AWARDS:**

1985	Gold Medal (Summa Cum Laude) Ministry of Education, Russia Federation, USSR and Golden Certificate of the USSR Ministry of Education
1991	Summa Cum Laude (Red MD Diploma)
2000	Special Award for organization St.-Petersburg Pavlov State Medical University, ul 6/8 Lev Tolst the 5th European Conference of St. Petersburg, Russia Neuro-Psycho-Pharmacology
2010	Top Doctor Certificate Pasadena Magazine, Pasadena, CA
2015, 2016, 2017 2019	The Leading Physicians of the International Association of HealthCare Professionals (IAHCP) World

**ACADEMIC APPOINTMENTS:**

1996-1998	Physician-Consultant	Comprehensive Diagnostic and Treatment Center, MSCh-11, Perm, Russia
1999-2001	Assistant Professor of Clinical Neuropharmacology	Department of Pharmacology, St.-Petersburg Pavlov State Medical University, St.-Petersburg, Russia
2006-2019	Assistant Professor of Clinical Neurology Attending Neurologist	Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
2019-present	Attending Neurologist	Department of Neurology, School of Medicine, LAC-USC

**TEACHING****DIDACTIC TEACHING:**

1995-1997	General Pathophysiology Perm State Academy of Pharmaceutical Sciences, Russia	700 hrs	Lecturer and proctor
1998-2000	Neuro-Pharmacology St-Petersburg Medical College; St.-Petersburg, Russia	1000 hrs	Lecturer and proctor
1999-2001	General Pharmacology and Neuro- Pharmacology St-Petersburg Pavlov State Medical University; St.- Petersburg, Russia	200 hrs	Lecturer and proctor

*Institution* University of Southern California

2007-present	Multiple Sclerosis: Pathophysiology and Diagnosis	4 hrs / year	Lecturer
2008-present	Differential Diagnosis of MS	6 hrs / year	Lecturer and proctor
2008-present	Pathoimmunology, Diagnosis and Treatment of MS exacerbations	4 hrs / year	Lecturer

2008-present	Multiple Sclerosis Disease- Modifying Treatments	8 hrs / year	Lecturer
2009-present	Emerging DMTs for MS	6 hrs / year	Lecturer
2007-2014	Summer Storm Series: Spinal cord emergencies	2 hrs / year	Lecturer
2006-2018	Neurological Examination for First Year Medical Students Workshop	3 hrs / year	Proctor

University of Southern California

#### **CME COURSES DEVELOPED**

2012-2015	Horizon CME Multiple Sclerosis in a Primary Care Setting: Employing Strategies for Early Diagnosis and Improved Patient Outcomes	6 hrs / year	Co-author (with Drs. F Lublin and Rivera)
2014	Multiple Sclerosis Association of America (MSAA) Pathophysiology, Immunology, Diagnosis and Treatment of MS exacerbations	12 hrs	Author and lecturer
2014, 2017	Multiple Sclerosis Association of America (MSAA). Immunomodulatory treatment options for Multiple Sclerosis	12 hrs	Author and lecturer
2015, 2017	Cure MS Fund Reproductive health and MS	12 hrs	Co-author (with Dr. Hutchinson of Harvard University) and lecturer
2015	Cure MS Fund Updates on MS	8 hrs	Author and lecturer
2016, 2017	MSAA Multiple Sclerosis Updates: What have I missed?	12 hrs	Author and lecturer
2016, 2017	Cure MS Fund MS Exacerbations	8 hrs	Author

**UNDERGRADUATE, GRADUATE AND MEDICAL STUDENT (OR OTHER) MENTORSHIP:**

2012-2013	Ilona Kravtsova	Undergraduate	Patient-reported outcomes based clinical research
2013-2014	Arthur Babayan	Undergraduate	Case report preparation
2016	Raffaello Bonacchi	Medical Student	Clinical report preparation and review
2017	Colin Matthew Hills	Medical Student	Clinical report preparation; professional expectations
2018	Jasmin Chao	Undergraduate	Professional development

**POSTGRADUATE MENTORSHIP:**

2011-2012	Robin Howard	USC Physical Therapy Associates
2012-2013	Eric Williamson, MD	MS fellow. Presently – University of Pennsylvania, Assistant Professor
2013-2014	Brandon Bieber, MD	MS fellow. Presently – Neurologist, Kaiser Permanente, Los Angeles
2015	Danielle Fenning	PT Neuro resident
2013	Amo Chilingarian, MD	Neurology Resident. Presently – Neurologist in private practice, Glendale, CA
2014-2015	Alex Gevorgian, MD	Neurology Resident
2016	Carly Lochala	PT Resident
2016	Erica Rivas, MD	MS Fellow
2017-2018	Erica Rivas, MD	MS Fellow
2017-2018	Lokesh Rukmangadachar, MD	MS Fellow
2017-2018	Mustafa Ansari, MD	MS Fellow

## **SERVICE**

### **PROFESSIONAL SERVICE:**

#### **CONSULTANTSHIPS AND ADVISORY BOARDS:**

2008-2016	Consultant, Advisory Board	Acorda
2008-2018	Co-Chair, Advisory Board	Bayer
2008-present	Co-Chair, Consultant, Moderator, Advisory Board	Biogen
2008-2018	Consultant, Advisory Board	Teva
2010-present	Co-Chair, Chair, Advisory Board	Sanofi
2013-present	Consultant, Co-Chair, Advisory Board	Novartis
2015, 2019-present	Consultant, Advisory Board	Genentec
2015-present	Multiple Sclerosis Association of America (MSAA) International Board Member	MSAA International Advisory Board
2015-present	National MS Society Board	NMSS Board
2015-present	MS Cure Fund Board Member	MS Cure Fund
2015-present	Co-Chair, Consultant, Steering Committee	Mallinckrodt
2019-present	Consultant, Advisory Board	Alexion
2018-present	Consultant, Advisory Board	Celgene

### **PROFESSIONAL SOCIETY MEMBERSHIPS:**

2006-present	Los Angeles Society of Neurologists
2006-present	American Academy of Neurology
2000-present	Russian Society of Neurologists

## **RESEARCH AND SCHOLARSHIP**

### **EDITORSHIPS AND EDITORIAL BOARDS:**

2015	Guest editor	Current Pharmaceutical Design
Since 2015	Associate Editor	Journal of Medical Case Reports

**MANUSCRIPT REVIEW:**

2014	CNS Neuroscience and Therapeutics journal
2014	CNS Neuroscience and Therapeutics journal
2015	Journal of Medical Case Reports
2015	CNS Neuroscience and Therapeutics journal
2015	Therapeutic Advances in Chronic Disease
2015	Journal of the Neurological Sciences
2015	Journal of Medical Case Reports
2015	Journal of the Neurological Sciences
2015	CNS Neuroscience & Therapeutics
2015	Journal of the Neurological Sciences
2015 - present	Therapeutic Advances in Neurological Disorders
2016 - present	Journal of Medical Case Reports
2016 - present	CNS Neuroscience & Therapeutics
2016	Journal of the Neurological Sciences
2017 - present	Multiple Sclerosis Journal

**MAJOR AREAS OF RESEARCH INTEREST**

1. Immunomodulation in Multiple Sclerosis and other CNS demyelinating disorders
2. MS and Autoimmune Comorbidities
3. Acute MS and NMO

**GRANT SUPPORT - CURRENT:****INVESTIGATOR INITIATED TRIAL (IIT) NATALIZUMAB GAP STUDY****SPONSOR: BIOGEN****ROLE: PI****INVESTIGATOR INITIATED TRIAL (IIT) CLINICAL AND MRI OUTCOMES OF TERIFLUNOMIDE PATIENTS****SPONSOR: SANOFI****ROLE: PI****MULTICENTER STUDY "CLICK MS"****SPONSOR: EMD SERONO****ROLE: PI**

EMD SERONO: “MASTER-2”

SPONSOR: EMD SERONO

ROLE: PI

**GRANT SUPPORT - PAST:**

Teva 9004: Follow-up study of the long-term, double-blind, placebo-controlled multicenter Phase III study to evaluate the efficacy and safety of Copaxone in patients with relapsing-remitting multiple sclerosis.

PI: Leslie P. Weiner, MD

Role: Co-PI; Examining Neurologist

TEVA Neuroscience, Inc.,

1994 - 2018

Total: \$465,000

*Grant No. (PI)*

*Dates of Award 2008-2010*

*Agency Questcor*

*Percent Effort*

*Title: Comparison of Monthly Pulse ACTH (ActharGel) Therapy with Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)*

*Description: Evaluator-blinded clinical trial*

*Role: PI*

*Total Direct Costs: \$540,000*

*Grant No. (PI)*

*Dates of Award 2010-2013*

*Agency Questcor*

*Percent Effort*

*Title: Comparison of Monthly Pulse ACTH (ActharGel) Therapy with Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif) - EXTENSION*

*Description: Extension open label clinical trial*

*Role: PI*

*Total Direct Costs: \$160,000*

*Grant No. (PI)*

*Agency Teva*

*Title: Evaluation of Effects of Glatiramer Acetate on Multiple Sclerosis Patients with Autoimmune Comorbidities*

*Role: PI*

*2011-present*

*Total Direct Costs: \$50,000*

## **INVITED LECTURES, SYMPOSIA, KEYNOTE ADDRESSES**



2009	Invited lecture	Investigator-Initiated Study: Pulse ACTH vs. MP. National MS Advisory Meeting, Questcor, Chicago, IL
2011	Plenary session presentation	Natalizumab reduces apathy in relapsing remitting multiple sclerosis patients. European NeuroPsychoPharmacology Congress (ECNP). St-Petersburg, Russia.
2011	Invited lecture	Multiple Sclerosis Summit. Questcor. Investigator-Initiated Study: Pulse ACTH vs. MP. New York, NY
2011	Keynote address	Role of ACTH in MS. National MS Society Research Meeting. San Francisco, CA
2012	Plenary Session presentation	National Congress of Pharmacology. Role of ACTH in MS treatment and Investigator Initiated Study. Kazan, Russia.
2013	Plenary Session presentation	Experience of using Natalizumab (Tysabri) for relapsing MS patient. RUCTRIMS (Russian Congress in MS therapy). Kazan, Russia
2013	Symposium presentation	21-year long term follow-up of the original Betaferon pivotal trial: survival data. World Congress of Neurology, Satellite Symposium. Vienna, Austria.
2014	Invited lecture	Clinical experience with Teriflunomide. [Launching of Aubagio in European Union]. Brussels, Belgium.
2014	Invited lecture	Clinical experience with Aubagio [Launching of Aubagio in Russian Federation]. Russian National Congress of Neurology. Yaroslavl, Russia
2015	USC MS Comprehensive Care Center presentation	Experience of long-term use of regular plasmapheresis for DMT-resistant progressive cases of MS: observational data. Presented at the USC MS Comprehensive Care Center meeting. Los Angeles, CA.
2015	USC MS Comprehensive Care Center presentation	Investigator-Initiated Studies and Observational studies: experience and relevant publications. Los Angeles, CA.
2015	Platform presentation	DMT Updates. RUCTRIMS. Yaroslavl, Russia
2015	Invited lecture	Investigator-Initiated Studies and Observational studies: experience and relevant publications. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2016	Invited lecture	Investigator-Initiated Study on ACTH and Observational studies. Royal Bucks Hospital, Reading, UK 11-21-16
2016	Invited lecture	Observational studies data and relevant publications. Kings Hospital, London, UK 11-22-16
2017	Keynote address	Experience with oral DMTs and Investigator-Initiated Studies. Institute of Neurological Sciences and University of Glasgow, Glasgow, United Kingdom
2017	Invited lecture	Experience with oral DMTs and Investigator-Initiated Studies Charing Cross Hospital, London, United Kingdom
2017	Invited lecture	Systemic Steroids vs Adrenocorticotrophic Hormone Pavlov State Medical University, St.-Petersburg, Russia
2017	Symposium	Disease-Modifying Therapies for MS and Investigator-Initiated Studies experience. National Neurologic Society. Pavlov State Medical University, St.-Petersburg, Russia

2017	International Congress	Continued below The evolving Spectrum of Disease-Modifying Therapies for Multiple Sclerosis: Opportunities and Risks. Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) 2017, Ho Chi Minh City, Vietnam
2017	Symposium	Evolving Spectrum of DMTs for MS: effects and risks. Bangalore Medical College and Research Institute. Bangalore, India
2017	Keynote	Disease-Modifying Therapies for MS and Investigator-Initiated Studies experience. University College of Medical Sciences. New Delhi, India
2017	Invited lecture	Disease-Modifying Therapies for MS: Updates in 2017. Multiple Sclerosis Association of America (MSAA), Los Angeles, CA, USA
2017	Invited lecture	Evolving Spectrum of DMTs for MS: opportunities and risks. Harbor UCLA, Department of Neurology Grand Rounds. Torrance, CA, USA
2018	Symposium	Multiple Sclerosis and DMTs for its treatment. Taiwan Neurologic Society. Taipei, Taiwan University
2018	Symposium "MS Beyond 2020"	Munich, Germany
2019	Invited lecture	DMTs and associated risks Krakow, Poland
2018	Keynote	Taipei University Grandrounds DMT landscape for MS Taipei, Taiwan
2019	Symposium	Hong Kong MS and Related disorders Symposium for Neurologists from Hong Kong, Taiwan and Macao
2019	CONFERENCE KEYNOTE SPEAKER	MULTIPLE SCLEROSIS AND NMOSD NEUROLOGY ASSOCIATION OF POLAND BYDGOSZCZ, POLAND

## INVITED GRAND ROUNDS, CME LECTURES

2006	CME	Updates to Multiple Sclerosis Treatment. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2006	CME	Principally new MS medication for MS: Natalizumab. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2008	Grand Rounds	New Approaches in MS treatment, Harbor UCLA Los Angeles, CA
2008	CME	Updates to Multiple Sclerosis Treatment. Investigator-Initiated study on ACTH. First St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2008	Grand Rounds	Updates to MS treatment, Marina Del Rey Hospital Los Angeles, CA
2009	Grand Rounds	Disease Modifying Treatment options for MS, Salinas Medical Center. Salinas, CA.
2009	CME	Updates to Multiple Sclerosis Treatment. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2009	Grand Rounds	Updates to MS treatment options, Tarzana Medical Center. Tarzana, CA
2009	Grand Rounds	ACTH for Multiple Sclerosis and Experience of Starting an Investigator Initiated Study, USC Keck School of Medicine, USC Neurology Los Angeles, CA
2009	CME	Experience of using Natalizumab. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2010	CME	Updates to Multiple Sclerosis Treatment. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2010	Grand Rounds	Experience of using Natalizumab. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2010	Grand Rounds	Depression as an MS symptom versus side effect of interferons. St.-Petersburg Pavlov State Medical University. St.-Petersburg, Russia
2010	Grand Rounds	Investigator-Initiated Trial. St.-Petersburg Pavlov State Medical University, St.-Petersburg, Russia
2010	Grand Rounds	New Approaches in treatment of advanced MS. Investigator Initiated Study on ACTH, Harbor UCLA. Los Angeles, CA
2011	Grand Rounds	MS and Autoimmune Comorbidities. Investigator-Initiated Trials. Stanford Medical School. Stanford, CA
2011	Grand Rounds	Potential Role of ACTH for long-term treatment of MS. Investigator-Initiated Trial. Harvard University. Cambridge, MA
2012	Grand Rounds	Clinical Cases Review. Providence Holy Cross Medical Center, Los Angeles, CA
2012	CME	Current DMTs for MS and proposed algorithm of use. Van Der Muellen Symposium. USC. Los Angeles, CA
2012	Grand Rounds	FDA-approved treatments for Multiple Sclerosis. University of Nevada.

2012	Grand Rounds	Las Vegas, NV Currently available Immunomodulatory treatment options for Multiple Sclerosis. USC Neurology. Los Angeles, CA
2012	Grand Rounds	ACTH in MS treatment; Investigator-Initiated trial on ACTH vs MP. St-Petersburg Pavlov State Medical University. St-Petersburg, Russia
2012	Grand Rounds	Role of ACTH in MS treatment; IIT design. Lahey Clinic, Tufts University School of Medicine. Burlington, MA.
2013	Grand Rounds	Updates on MS DMTs and on my IITs. St-Petersburg Pavlov State Medical University. St-Petersburg, Russia.
2013	CME	MS management for the primary care settings. Anaheim, California
2013	Grand Rounds	Updates on MS DMTs. Investigator-Initiated Studies on ACTH. University of Nevada. Las Vegas, NV
2013	CME	Currently available Immunomodulatory treatment options for Multiple Sclerosis. NY Neurology associates. New York, NY
2013	CME	Finding the right DMT for the right MS patient. Neurology Symposium. Ulyanovsk, Russia
2014	CME	Immunomodulatory treatment options for Multiple Sclerosis. MSAA. Oregon.
2014	Grand Rounds	Finding the right DMT for the right MS patient. Clinical experience with Tysabri. Neurology Symposium. Novosibirsk, Russia
2014	CME	Immunomodulatory treatment options for Multiple Sclerosis. MSAA. Las Vegas, NV
2014	CME	Immunomodulatory treatment options for Multiple Sclerosis. San Diego, CA
2014	CME	Immunomodulatory treatment options for Multiple Sclerosis. Phoenix, AZ.
2014	CME	Changing landscape of treatments for Multiple Sclerosis. MSAA. Phoenix, AZ.
2015	Grand Rounds	Oral DMTs: can the three be more different? Observational study data. Updates on research projects. Neurology Association of Hawaii. Honolulu, HI
2015	Grand Rounds	Oral DMTs: from MoA to safety and clinical observations. Our clinical observational study data. San Diego Neurology Associates Meeting. San Diego, CA
2015	Grand Rounds	Multiple Sclerosis 2015 updates. Hope Conference Center at Providence Saint Joseph Medical Center. Burbank, CA
2016	Grand Rounds	Updates in MS DMTs and Investigator-Initiated Study. USC Neurology Los Angeles, CA
2016	Grand Rounds	Real world experience with current DMTs and Investigator-Initiated studies. Canterbury hospital, Canterbury, UK 11-23-16
2016	Grand Rounds	Real world US experience with current DMTs and Investigator-Initiated studies. St George's hospital, London, UK 11-24-16
2016	Grand Rounds	Real world US experience with current DMTs and Investigator-Initiated studies. Charing Cross hospital, London, UK 11-25-16

2016	CME	Rexperience with current DMTs and Investigator-Initiated studies.Chicago, MSAA
2016	CME	Experience with current DMTs and Investigator-Initiated studies.Spokane, MSAA
2017	CME	Experience with oral DMTs and Investigator-Initiated Studies. Institute of Neurological Sciences and University of Glasgow, Glasgow, United Kingdom
2017	Grand Rounds, CME	Experience with oral DMTs and Investigator-Initiated Studies Charing Cross Hospital, London, United Kingdom
2017	Grand Rounds, CME	Disease-Modifying Therapies for MS and Investigator-Initiated Studies experience. University College of Medical Sciences. New Delhi, India
2017	Grand Rounds, CME	Evolving Spectrum of DMTs for MS: effects and risks. Bangalore Medical College and Research Institute. Bangalore, India
2017	Grand Rounds	Disease-Modifying Therapies for MS and Investigator-Initiated Studies experience. National Neurologic Society. Pavlov State Medical University, St.-Petersburg, Russia
2017	Grand Rounds, CME	Evolving Spectrum of DMTs for MS: opportunities and risks. Harbor UCLA, Department of Neurology Grand Rounds. Torrance, CA, USA
2017	Grand Rounds	Systemic Steroids vs Adrenocorticotrophic Hormone Pavlov State Medical University, St.-Petersburg, Russia
2017	CME	Post-ECTRIMS Updates on MS (USC Keck MS Symposium)
2019	Grand Rounds	DMTs: Risk perception of MS patients and MS neurologists Reflections following AAN 2019 poster presentation Pavlov Medical University St. Petersburg, Russia

#### THESIS:

<i>Year</i>	<i>Degree</i>	<i>Institution</i>	<i>Title</i>
1996	Philosophy Doctor (PhD)	Kazan Medical Academy, Russia	Hypolipidemic Effects of the tranquillizer Mebicar

## PUBLICATIONS

### PEER REVIEWED PUBLICATIONS /

#### REFERRED JOURNAL ARTICLES (CHRONOLOGICALLY):

1. Zimakova IE, **Salikhova RR (aka Berkovich RR)**, Garaev RS. The impact of tranquillizer Mebicar on the lipid metabolism on the model hypokinesia of rats. *Experimental Biology and Medicine*. 6:124-136, 1996. PMID: 8744131 *Personal contribution All experimental work, data collection and analysis, writing.*
2. Rison RA and **Berkovich R**. Teaching Neurolmages: Hiccoughs and vomiting in neuromyelitis optica. *Neurology*, Vol. 75, No 17, e70, 2010. PMID: 20975046 *Personal contribution: clinical observation, data collection, co-writing the manuscript.*
3. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; **Berkovich RR** SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. *J Neurol Sci*. 292(1-2):28-35, 2010. PMID: 20236661 *Personal contribution: clinical investigator; reviewed, edited and approved the manuscript.*
4. **Berkovich R**, Subhani D, Steinman L. Autoimmune Comorbid Conditions in Multiple Sclerosis. *US Neurology*; 7(2):132-138, 2011. *Personal contribution: original idea, data collection, literature review and writing.*
5. Arnason B, **Berkovich R**, Catania A. et al. *Therapeutic mechanisms of action of adrenocorticotrophic hormone (ACTH) and other melanocortin peptides for the clinical management of patients with MS*. *Multiple Sclerosis*;19(2):130-136, 2013. PMID: 23034287 *Personal contribution: clinical data collection, literature review and writing.*
6. **Berkovich R**. Treatment of acute relapses in Multiple Sclerosis. *Neurotherapeutics*. Jan;10(1):97-105, 2013. PMID: 23229226 *Personal contribution: clinical observations and data collection, literature review and writing.*
7. Sokolov AY, Lyubashina OA, Sivachenko IB, **Berkovich RR**, Panteleev SS. Intravenous valproate inhibits ongoing and evoked activity of dura-sensitive thalamic neurons in rats. *Eur J Pharmacol*. 5;715(1-3):204-211, 2013. PMID: 23732564 *Personal contribution: data review, discussion, editing and approval of the final manuscript.*
8. **Brkovich RR (aka Berkovich RR)**, Totolyan NA, Sokolov AY at al. Treatment of relapses in multiple sclerosis. *Korsakoff Journal of Neurology and Psychiatry* /**Беркович РР**, Тотолян НА, Соколов АЮ, Игнатов ЮД, Скоромец АА. Лечение обострений рассеянного склероза (обзор). *Журнал неврологии и психиатрии им. С.С. Корсакова*], №10:69-77, 2013. PMID: 24416811 *Personal contribution: clinical observations, literature review and writing.*

9. **Berkovich R** and Agius MA. Mechanisms of Action of ACTH in the Management of Relapsing Forms of Multiple Sclerosis. *Therapeutic Advances in Neurological Disorders*. 7(2):83-96, 2014. PMID: 24587825 *Personal contribution: original idea and concept, literature review and writing*.
10. Sokolov AY, Lyubashina OA, **Berkovich RR** et al. Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats. *European Journal of Pain*. 19(8):1086-1094, 2014. PMID: 23732564 *Personal contribution: original idea and concept, clinical observations, literature review and writing*.
11. **Regina Berkovich**, Daniel M. Togasaki, Steven Y. Cen and Lawrence Steinman. CD4 cell response to interval therapy with natalizumab. *Annals of Clinical and Translational Neurology*. 2(5): 570–574. 2015. PMID: 26000328 *Personal contribution: original idea, clinical observations and data collection, literature review and writing*.
12. **Berkovich R** and Weiner LP. Effects of dimethyl fumarate on lymphocyte subsets. *Multiple Sclerosis and Related Disorders*. 4:339–341, 2015. PMID: 26195053 *Personal contribution: original idea, clinical observations and data collection, literature review and writing*.
13. **Berkovich R**, Bakshi R, Amezcua L, Axtell R, Cen S, Tauhid S, Neema M and Steinman L. Adrenocorticotrophic hormone versus methylprednisolone added to interferon in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. *Therapeutic Advances in Neurological Disorders*; Oct 19, 2016 Vol. 10(1) 3-17 DOI: 10.1177/1756285616670060 *Personal contribution: original idea and study design, principal investigator, literature review and writing*
14. **Berkovich R**. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report. *Multiple Sclerosis and Related Disorders*. 2017 Oct;17:123-127. DOI: 10.1016/j.msard.2017.07.007. Epub 2017 Jul 6. *Personal contribution: original idea and study design, data collection, literature review and writing*.
15. Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, **Berkovich R**, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. *Neurol Clin Pract*. 2018 Apr;8(2):102-107. doi:10.1212/CPJ.0000000000000434.
16. **Berkovich RR**, Sokolov AY, Togasaki DM, Yakupova AA, Cesar PH, Sahai-Srivastava S. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study. *Clin Neuropharmacol*. 2018 Mar/Apr;41(2):64-69. doi: 10.1097/WNF.0000000000000272. *PERSONAL CONTRIBUTION: ORIGINAL IDEA AND STUDY DESIGN, DATA COLLECTION, LITERATURE REVIEW AND WRITING*

**17. Berkovich R. Experience of Using Adrenocorticotrophic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series.**

*Clin Neuropharmacol.* 2019 Dec 24. doi: 10.1097/WNF.0000000000000373. PMID: 31876792

18. Comi G, Alroughani R, Boster AL, Bass AD, **Berkovich R**, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. [Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.](#) *Mult Scler.* 2019 Nov 25;1352458519888610. doi: 10.1177/1352458519888610. PMID:31762387
19. Okai AF, Amezcua L, **Berkovich RR**, Chinea AR, Edwards KR, Steingo B, Walker A, Jacobs AK, Daizadeh N, Williams MJ; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. [Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II \(TOPAZ Study\).](#) *Neural Ther.* 2019 Dec;8(2):367-381. doi: 10.1007/s40120-019-00159-2. Epub 2019 Oct 25. PMID:31654272
20. Efficacy of a fourth alemtuzumab course in RRMS patients with disease activity after three prior courses: analysis of CARE-MS I Published: 2018 in European Journal of Neurology  
Identifying disability level in multiple sclerosis patients in a US-based health plan claims database Published: Jan 2021 in Journal of Medical Economics DOI: 10.1080/13696998.2020.1857257
21. Efficacy of a Third Course of Alemtuzumab in Patients with Active RelapsingRemitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses: Pooled Analysis of CARE-MS I and II Published: 2018 in Multiple Sclerosis Journal
22. 7-year outcomes in MS patients of African descent treated with alemtuzumab: follow-up of CARE-MS I and II (TOPAZ Study) Published: 2018 in Multiple Sclerosis Journal
23. Additional courses of alemtuzumab improved clinical and MRI outcomes in pooled CARE-MS I and II patients with disease activity after two courses: analysis of patients who received  $\geq 3$  courses Published: 2018 in Multiple Sclerosis Journal
24. Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity after the Initial Two Courses: Results from the CARE-MS II Extension Published: 2018 in Multiple Sclerosis Journal 0
25. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study Published: 2018 in Clinical Neuropharmacology DOI: 10.1097/WNF.0000000000000272 0
26. Additional courses of alemtuzumab improved clinical and MRI outcomes in pooled CARE-MS I and II patients with disease activity after three courses: analysis of patients who received  $\geq 4$  courses Published: 2018 in Multiple Sclerosis Journal 0
27. Long-term efficacy and safety of Alemtuzumab in patients with RRMS: 12-year follow-up of the CAMMS223 study Published: 2019 in Multiple Sclerosis Journal 1 Effectiveness of alternative dose fingolimod for multiple sclerosis Published: Apr 2018 in Neurology Clinical Practice DOI: 10.1212/CPJ.0000000000000434 7
28. Long-Term Outcomes in Patients with Progressive Forms of Relapsing MS Treated with Teriflunomide: Real-World Evidence Published: Feb 2018 in Multiple Sclerosis Journal 0



29. Assessment of clinical disease activity and disability improvement by number-needed-to-treat analyses in patients with relapsing multiple sclerosis treated with alemtuzumab or ocrelizumab Published: Feb 2018 in Multiple Sclerosis Journal 0
30. Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS I Extension Published: 2018 in Neurology 0
31. Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension Published: 2018 in Neurology 0
32. Long-Term Outcomes in Patients With Progressive Forms of Relapsing MS Treated With Teriflunomide: Real-World Evidence Published: 2018 in Neurology 0
33. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study) Published: Dec 2019 in Neurology and Therapy DOI: 10.1007/S40120-019-00159-2 0
34. Identifying disability level in multiple sclerosis patients in a US-based health plan claims database Published: Sep 2019 in Multiple Sclerosis Journal
35. 0 Number Needed to Treat to Prevent Relapse and Disability Worsening Among Patients with Relapsing MS Treated with Teriflunomide or Cladribine Published: Apr 2019 in Neurology
36. 7-Year Outcomes in MS Patients of African Descent Treated With Alemtuzumab: Follow-up of CARE-MS I and II (TOPAZ study) Published: Apr 2019 in Neurology 0
37. Disability Level and Comorbidity Burden among Multiple Sclerosis (MS) Patients in the US Published: Apr 2019 in Neurology 0 PML Risk Perception in Patients Initiating Natalizumab for Multiple Sclerosis Published: 2019 in Neurology 0
38. Additional Courses of Alemtuzumab Improved Clinical and MRI Outcomes in Pooled CARE-MS I and II Patients With Disease Activity After Two Courses: Analysis of Patients Who Received  $\geq 3$  Courses Published: 2019 in Multiple Sclerosis Journal 0
39. Treatment With Additional Courses of Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients With Disease Activity After Three Courses: Analysis of CARE-MS Patients Who Received  $\geq 4$  Courses Published: 2019 in Neurology 0
40. Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years Published: 2019 in European Journal of Neurology 0
41. Real-world experience in rrms and spms patients with higher disability and substantial lymphopenia switching from prior dmts to teriflunomide Published: Dec 2020 in Multiple Sclerosis Journal 0
42. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study Published: Sep 2020 in CNS Drugs DOI: 10.1007/S40263-020-00749-X 1
43. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 Published: Jun 2020 in Journal of Neurology DOI: 10.1007/S00415-020-09983-1 1 Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ) Published: May 2020 in European Journal of Neurology 0
44. Experience of Using Adrenocorticotrophic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series Published: 2020 in Clinical Neuropharmacology DOI: 10.1097/WNF.0000000000000373 0

45. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CAREMS, extension, and TOPAZ studies  
Published: Dec 2020 in Multiple Sclerosis Journal DOI: 10.1177/1352458519888610 8

#### REFEREED REVIEWS, CHAPTERS, AND EDITORIALS:

1. **Berkovich RR**. Acute Multiple Sclerosis Relapse. *American Academy of Neurology. Continuum* (Minneapolis Minn). 2016 Aug;22(3):799-814. Doi: 10.1212/CON.0000000000000330
2. **Berkovich R**. Book chapter: Immunology and treatment of acute relapses in MS. *Translational Neurology*.
3. **Berkovich R**. Book Chapter: Immunology of MS in the book "Multiple Sclerosis for the Non-Neurologist". Wolters Kluwer, 2019

#### REFEREED ON-LINE PUBLICATIONS:

1. **Berkovich R**, Kantor D, Reder AT, editor. Multiple sclerosis: treatment of its symptoms. MedLink Neurology. San Diego: MedLink Corporation. Available at [www.medlink.com](http://www.medlink.com). Publication dates: Originally released September 11, 2002; last updated March 4, 2013; expires March 4, 2016  
[http://www.medlink.com/article/immunomodulatory\\_agents\\_in\\_ms\\_clinical\\_trials\\_and\\_therapy](http://www.medlink.com/article/immunomodulatory_agents_in_ms_clinical_trials_and_therapy)
2. **Berkovich R**, Kantor D, Reder AT, editor. Immunomodulatory agents in MS: clinical trials and therapy. MedLink Neurology. San Diego: MedLink Corporation. Available at [www.medlink.com](http://www.medlink.com). Publication dates: Originally released November 12, 2002; last updated June 10, 2013; expires June 10, 2016  
[http://www.medlink.com/article/multiple\\_sclerosis\\_treatment\\_of\\_its\\_symptoms](http://www.medlink.com/article/multiple_sclerosis_treatment_of_its_symptoms)

#### NON-REFEREED JOURNAL ARTICLES, REVIEWS, OR OTHER COMMUNICATIONS:

1. Zimakova IE, **Salikhova RR (aka Berkovich R)**, Tagirova TS, Karpov AM. The use of Mebicar for complex therapy of atherosclerosis. *Kazan State Medical Academy Methodological Recommendations*. 1:1-22, 1995.
2. **Salikhova RR (aka Berkovich R)**. The impact of the tranquilizers Mebicar and Seduxen on the lipid metabolism and lipid peroxidation. *The Thesis's of the Conference of Young Scientists, Kazan State Medical Academy*. 1:73–76, 1996.
3. Zimakova IE, Garaev RS, **Salikhova RR (aka Berkovich R)**. Stress protective and hypolipidemic effects of Mebicar. *The Theses of the 2nd Russian National Congress "Human Being and Medicine"*, Moscow, 2:295–296, 1995.
4. Dautova RK, Zimakova IE, Tagirova TS, **Salikhova RR (aka Berkovich R)**. The potential use of Mebicar in correction of metabolism. *Modern Problems of Psychiatry*. 67-69, 1994.
5. Tagirova TS, Zimakova IE, **Salikhova RR (aka Berkovich R)**. Hypolipidemic Effects of Mebicar. *Modern Problems of Psychiatry*. 124–125, 1994.
6. Tagirova TS, Zimakova IE, **Salikhova RR (aka Berkovich R)**. Effects of Mebicar in correction of lipid metabolism in rats. *The Thesis's of the Republic Scientific Conference*. 116–118, 1994.
7. **Salikhova RR (aka Berkovich R)**. The impact of anti anxiety medication Mebicar on the Malonaldehyde contents in tissues and blood lipid spectrum of rats. *The Journal of the European College of Neuropsychopharmacology*. 10:69, 2000.
8. **Berkovich R**. Natalizumab reduces apathy in relapsing remitting multiple sclerosis patients. *European Neuropsychopharmacology*. 21:154-155, 2011.
9. **Беркович РР**. Воспоминания о Юрии Дмитриевиче.

## BOOKS, MONOGRAPHS, AND TEXT BOOKS:

**Berkovich R.** "See a Bigger Picture" for Children who have a parent with Multiple Sclerosis. Written and Illustrated by Regina Berkovich, MD, PhD, MS Specialist - sponsored by Teva Neuroscience, 38 pages, 100.000 copies, 2011.

## SELECTED ABSTRACTS AND PLATFORM PRESENTATIONS:

Amezcu L, **Berkovich R**, Tsao-Wei D et al. IFN  $\beta$ 1a induced changes in myelin-specific T cell frequency may serve as a biomarker predicting clinical outcome. The Twelfth Annual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) June 2, 2007.

**Berkovich R.** Four cases of co-morbid multiple sclerosis and psoriasis: sustained remission of both conditions while on natalizumab. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology; 2010 April 10-17; Toronto, Canada.

**Berkovich R**, Spann B. Apathy in multiple sclerosis and its association with depression, fatigue, and cognitive impairment. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology; 2010 April 10-17; Toronto, Canada.

Amezcu L, **Berkovich R**, Burnett M, Aparicio J, Kachuck N. Expanded laboratory surveillance for PML in a large cohort of patients on natalizumab for multiple sclerosis. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology; 2010 April 10-17; Toronto, Canada.

Lerner A, **Berkovich R**, Law M. DTI in multiple sclerosis patients with and without apathy. Poster presented at: 48th Annual Meeting of the American Society for Neuroradiology; 2010 May 15-20; Boston, MA.

**Berkovich R**, Gilmore W, Lund B. Monthly pulse adrenocorticotropin hormone versus methylprednisolone for multiple sclerosis treatment. International Journal of MS Care. 2010;12 (suppl 1):81.

Williamson E, Subhani D and **Berkovich R**. Case report: Progressive encephalopathy in Multiple Sclerosis patient responsive to plasma exchange. CMSC 2012 abstracts\_Int J of MS Care pg 46-47

**Berkovich R.** Role of ACTH in MS. National MS Society Research Meeting. San Francisco, August 2011.

**Berkovich R**, Fernandez M, Subhani S. Monthly pulse adrenocorticotropin hormone (ACTH) or methylprednisolone therapy for long-term treatment of multiple sclerosis as an add-on therapy to beta-interferons: interim results from a pilot study. Multiple Sclerosis.ECTRIMS 2011; 17(suppl 1): S249-250. Amsterdam, Netherlands.

**Berkovich R**, Fernandez M, Subhani D. "Adrenocorticotropin hormone treatment of multiple sclerosis exacerbations" CMSC- ACTRIMS 2012; Abstract DX66. San Diego, CA.

**Berkovich R**, Togasaki D, Subhani D, Steinman L. Dynamics of the peripheral blood CD4 cell counts of JCV Ab positive patients at the different phases of natalizumab treatment. ECTRIMS October 12, 2012, Lyon, France.

**Berkovich R**, Amezcu L, Subhani D, Cen S. Pilot study of monthly pulse adrenocorticotropin hormone (ACTH) or methylprednisolone as an add-on therapy to beta-interferons for long-term treatment of multiple sclerosis. Presented at the American Academy of Neurology's 65 th Annual Meeting. San Diego, CA. March 16 - 23, 2013. Neurology 2013; 80(19): e205-e206

Amezcu L, Axtell R, Cen S, Tauhid S; Neema M, Subhani D, Bakshi R, Steinman L & **Berkovich R**. Pilot Study of Monthly Pulse Adrenocorticotropin Hormone or Methylprednisolone as an Add-on Therapy to  $\beta$ -interferons for Long-term Treatment of Multiple

Sclerosis. Presented at the 29th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 2-5, 2013. (P1097). Multiple Sclerosis. October 2013; 19(11 suppl): 514-151. Copenhagen, Denmark.

Totolyan N, **Berkovich R**. Alemtuzumab safety data – presented at the Congress of the Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS). September 2015. Yaroslavl. Russia.

Javed A, **Berkovich R**, Hendin B, Miller A, Tornatore C. Use of patient case scenarios to assess current practice patterns of MS relapse assessment and treatment among MS specialists in the United States. P671. ECTRIMS October 8, 115567, 2015. Barcelona, Spain

LaGanke C, Hughes B, **Berkovich R**, Cohen J, Giovannoni G, Kasten L, Margolin D, Havrdova E. ; on behalf of the CARE-MS II Investigators Durable Effect of Alemtuzumab on Disability Improvement in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy. P3.261. 67th Annual Meeting of the American Academy of Neurology (AAN) April 18–25, 2015. Washington, DC, USA

Giovannoni G, **Berkovich R**, Fernandez O, Fox E, Wiendl H, Margolin D, Kasten L, LaGanke C; on behalf of the CARE-MS II Investigators. Durable Improvement in Expanded Disability Status Scale Functional Systems Scores Over 4 Years With Alemtuzumab Despite a Majority of Patients Not Receiving Treatment Since Year 1. P1104. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) October 7–10, 2015. Barcelona, Spain

Khan, O., **Berkovich, R.**, Hendin, B., Javed, A., Miller, C., Tornatore, C. Current practice patterns of MS management among MS specialists in the United States: survey results of the MS relapse practice patterns project. ECTRIMS, October 2017, Paris, France

**Berkovich, R.**, Aparicio, J., Tarlow, L., Palomeque, A., Amezcua, L. A non-randomized, open label, exploratory study of dalfampridine-extended release and sexual dysfunction in women with multiple sclerosis. ECTRIMS, October 2017, Paris, France

Javed, A., **Berkovich, R.**, Hendin, B., Miller, A., Tornatore, C. Use of patient case scenarios to assess current practice patterns of MS relapse assessment and treatment among MS specialists in the United States. ECTRIMS, October 2017, Paris, France

#### AAN Platform Presentation (MS and CNS Inflammatory Disease, April 24, 2017)

006 A. Rovira (Vall d'Hebron University Hospital), A. Boster (Ohio State University), G. Comi (University Vita-Salute San Raffaele), **R. Berkovich** (University of Southern California, Keck School of Medicine), D. Pelletier (University of Southern California, Keck School of Medicine), S. Schippling (University Hospital), A. Traboulsee (University of British Columbia), C. LaGanke (North Central Neurology Associates, PC), D. Margolin (Sanofi Genzyme), S. Santra (Cytel), D. Arnold (NeuroRx Research), o. Investigators. Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study .

#### AAN Platform Presentation (MS and CNS Inflammatory Disease, April 26, 2017)

I. Kister (NYU School of Medicine, NY), D. Kantor (Kantor Neurology), S. Khoury (Nehme and Therese Tohme MS Center), M. Rice (MS Center of Tidewater), E. Lathi (The MS Ctr/Dept of Neuro), A. Caminero Rodriguez (C/ Fuentes Claras #1), S. Pawate (Vanderbilt University Medical Center), M. Bradshaw, MD (Vanderbilt University Medical Center), K. Edwards (MS Center of Northeastern NY - Empire Neurology, P.C.), A. Cross (Washington University School of Medicine), B. Parks (Washington University School of Medicine), J. Lynch (CoxHealth), R. Archer (University of Arkansas for Medical Sciences), W. Meador (The University of Alabama at Birmingham), **R. Berkovich** (Keck School of Medicine of USC), B. Yamout (American University of Beirut), M. Zeineddine (American University of Beirut), D. VanderKodde (Spectrum Health Medical Group), G. Von Geldern (University of Wisconsin Medical Center), L. Ge (NYU School of Medicine), S. Russell (BarnabasRWJ), T. Bacon (NYU School of Medicine, NY), E. Longbrake (Yale University)

007 Alternate dosing of fingolimod for Multiple Sclerosis. AAN 2017

**R. Berkovich** (Keck School of Medicine of USC). Effects of Alemtuzumab on Disability and Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS). AAN 2017

E. Williamson (University of Pennsylvania Penn Neuroscience Center), H. Zhang

J. Aldridge, S. Baver, **R. Berkovich** (University of Southern California) Efficacy of Interferon  $\beta$ -1a Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Subgroups: Post Hoc Analysis of PRISMS Data. AAN 2017

G. Comi (University Vita-Salute San Raffaele), R. Alroughani (Amiri Hospital), **R. Berkovich** (University of Southern California, Keck School of Medicine), et al. Number Needed to Treat Analyses to Assess Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab or Ocrelizumab. AAN 2017

Aaron Boster, MD , OhioHealth Neurological Physicians, Columbus, OH; Raed Alroughani, MD , Amiri Hospital; Sharq, Kuwait; **Regina Berkovich, MD, PhD** , University of Southern California, Keck School of Medicine, Los Angeles, CA; Giancarlo Comi, MD et al. Number Needed to Treat Analyses Comparing Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Alemtuzumab or Ocrelizumab. CMSC. May 25, 2017. B2 (New Orleans Convention Center).

Anthony Traboulsee, MD , University of British Columbia, Vancouver, BC, Canada; Michael Barnett, PhD, MD , University of Sydney, Sydney, NSW, Australia; **Regina Berkovich, MD, PhD** , University of Southern California, Keck School of Medicine, Los Angeles, CA; Aaron Boster, MD , OhioHealth Neurological Physicians, Columbus, OH; Giancarlo Comi, MD , University Vita-Salute San Raffaele, Milan, Italy; CARE-MS I and CAMMS03409 Investigators, n/a , MA. Durable Efficacy of Alemtuzumab on MRI Disease Activity over 6 Years in Treatment-Naive RRMS Patients with Highly Active Disease: Care-MS I Extension. CMSC, May 25, 2017. B2 (New Orleans Convention Center).

**Regina Berkovich, MD, PhD**, MS Comprehensive Care Center and Research Group, University of Southern California, Los Angeles, CA; Hao Zhang, PhD, EMD Serono, Inc., Billerica, MA; Julie Aldridge, MS, EMD Serono, Inc., Billerica, MA; Scott Bayer, PhD, EMD Serono, Inc., Rockland, MA; Eric Williamson, MD, University of Pennsylvania Penn Neuroscience Center, Philadelphia, PA; Mary Lee, NA, Caudex, New York, NY; Michele Springer, BA, Caudex, New York, NY. Post Hoc Analysis of PRISMS Study: Efficacy of Interferon beta-1a Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Subgroups. CMSC, May 25, 2017. B2 (New Orleans Convention Center).

Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database. Scientific session.

Platform presentation.ECTRIMS. Stockholm, Sweden. **Berkovich R.** Sep 13, 2019; 279554; 293

## **MEDIA AND TELEVISION APPEARANCES:**

1. 2009, Interview for the *Burbank Leader* "Reaching for the sky" October 24, 2009
2. 2014, Interview by Olga Rukovets, Pregnancy Hormone found to Reduce Relapses in Women with MS. *Neurology Today*, June 19, 14(12), 8.
3. 2015, Interview by Jack Osborn for his program "You don't know Jack", USC
4. 2017, Interview by Martin Booe, *Staying on Course*. USC Health, A Publication of Keck Medicine of USC. Vol. 2017 Issue 1, 12-13.
5. 2019, National Radio podcasts. Series of Interviews on Secondary Progressive Multiple Sclerosis.